Skip to Main Content

Evaluation of abrocitinib in the treatment of generalized granuloma annulare

  • Study HIC#:2000033312
  • Last Updated:11/02/2023

Participants with generalized granuloma annulare will be treated with abrocitinib 200 mg once daily (there is no placebo group). We will evaluate changes in the activity and extent of granuloma annulare as a result of treatment. The treatment duration in 6 months and visits at 0, 1, 3, and 6 months are required.

  • Age18 years and older
  • GenderBoth

Contact Us

For more information about this study, including how to volunteer, contact:

Nicole Olszewski

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.

Trial Purpose and Description

Participants with generalized granuloma annulare will be treated with abrocitinib 200 mg once daily (there is no placebo group). We will evaluate changes in the activity and extent of granuloma annulare as a result of treatment. The treatment duration in 6 months and visits at 0, 1, 3, and 6 months are required.

Eligibility Criteria

Participants must have a diagnosis of granuloma annulare and be 18 years of age or older. Participants may not be taking any other oral or injected therapies for their granuloma annulare at the time of study enrollment.

For more information about this study, including how to volunteer, contact: